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Abstract
Hepatitis C virus (HCV) establishes infection using host lipid metabolism pathways that are thus considered potential targets
for indirect anti-HCV strategies. HCV enters the cell via clathrin-dependent endocytosis, interacting with several receptors,
and virus-cell fusion, which depends on acidic pH and the integrity of cholesterol-rich domains of the hepatocyte
membrane. The ATP-binding Cassette Transporter A1 (ABCA1) mediates cholesterol efflux from hepatocytes to extracellular
Apolipoprotein A1 and moves cholesterol within cell membranes. Furthermore, it generates high-density lipoprotein (HDL)
particles. HDL protects against arteriosclerosis and cardiovascular disease. We show that the up-regulation of ABCA1 gene
expression and its cholesterol efflux function in Huh7.5 hepatoma cells, using the liver X receptor (LXR) agonist GW3965,
impairs HCV infection and decreases levels of virus produced. ABCA1-stimulation inhibited HCV cell entry, acting on virus-
host cell fusion, but had no impact on virus attachment, replication, or assembly/secretion. It did not affect infectivity or
properties of virus particles produced. Silencing of the ABCA1 gene and reduction of the specific cholesterol efflux function
counteracted the inhibitory effect of the GW3965 on HCV infection, providing evidence for a key role of ABCA1 in this
process. Impaired virus-cell entry correlated with the reorganisation of cholesterol-rich membrane microdomains (lipid
rafts). The inhibitory effect could be reversed by an exogenous cholesterol supply, indicating that restriction of HCV
infection was induced by changes of cholesterol content/distribution in membrane regions essential for virus-cell fusion.
Stimulation of ABCA1 expression by GW3965 inhibited HCV infection of both human primary hepatocytes and isolated
human liver slices. This study reveals that pharmacological stimulation of the ABCA1-dependent cholesterol efflux pathway
disrupts membrane cholesterol homeostasis, leading to the inhibition of virus–cell fusion and thus HCV cell entry. Therefore
besides other beneficial roles, ABCA1 might represent a potential target for HCV therapy.
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Introduction
Hepatitis C virus (HCV) infection affects 3% of the world
population and is major cause of chronic liver disease with severe
hepatic consequences such as steatosis, cirrhosis and hepatocar-
cinoma. Recently, numerous direct acting anti-viral drugs (DDA)
have been introduced, which target essential viral functions. These
new treatments represent a significant step forward compared to
standard Pegylated IFN-a-ribavirin therapy. DDA are mainly
inhibitors of NS3/NS4 HCV protease, and others drugs are under
development that target the NS5B polymerase or NS5A that also
play essential roles in HCV replication [1]. However, these DDA
still have side effects and induce the manifestation of drug-
resistance [2]. Novel treatments targeting host cell molecules
involved in various steps of the HCV life cycle (such as cyclophilin
A, microRNA-122, or phosphatidylinositol-4-kinase III alpha)
have been proposed for novel anti-HCV approaches (and these are
called ‘‘indirect acting anti-viral drugs’’, IAAD), to prevent the
onset of antiviral resistance and to cure infection with all HCV
genotypes [1,3].
HCV is an enveloped virus of the Flaviviridae family (genus
Hepacivirus) with a single-stranded positive RNA genome of 9.6 kb.
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The viral genome encodes a polyprotein of 3,000 amino acids,
which is cleaved by the host and viral proteases into structural
proteins (the capsid protein and two envelope glycoproteins E1
and E2), P7 and several non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A and NS5B) involved in genome replication and virus
assembly [3,4].
Lipids and lipoproteins are essential for the HCV life cycle
[5,6,7]. HCV has developed lipoprotein-dependent mechanisms
for cell entry [8,9,10], replication regulated by fatty acids [11],
virus morphogenesis that is linked to lipid droplets [12] and the
assembly and release of infectious virions via the VLDL (very low
density lipoprotein) formation and secretion pathway [13,14].
Consequently, HCV circulates in the plasma of infected patients in
association with VLDL and LDL (low-density lipoprotein),
forming lipo-viral particles (LVPs) [15,16].
The relationships between lipid metabolism and HCV are
complex and intriguing. The expression of host genes involved in
biosynthesis, degradation or transport of intracellular lipids is
altered upon HCV infection [17,18]. Steatosis and insulin
resistance associated with the metabolic syndrome increase fibrosis
progression and reduce the response to the IFN-a-ribavirin
treatment. Moreover, a high baseline LDL level has been shown
to be the best predictor of a sustained virologic response, whereas
low lipid levels correlate with steatosis, progressing fibrosis and
non-response to treatment [19].
Altogether, these observations reflect the important role of lipids
in the HCV life cycle. Therefore, host factors involved in
cholesterol/lipid metabolism might represent potential targets for
HCV strategies, with only limited possibilities for escape mutations
to develop [20,21] and allowing treatment of patients infected with
genotype 3 HCV [1].
Cholesterol is an important structural component of biological
membranes and is essential for the uptake of many viruses. HCV
cell entry requires cholesterol homeostasis and intact cholesterol-
rich membrane microdomains [22]. Indeed perturbation of the
alignment/packaging of cholesterol in lipid membranes increases
the energy barrier required for virus-cell entry via fusion
mechanisms [23].
Hepatocytes play a vital role in cholesterol homeostasis,
acquiring cholesterol by synthesis via the mevalonate pathway or
by LDL-R mediated endocytosis. Cholesterol is exported from
hepatocytes together with triglycerides through the VLDL
secretion pathway [24]. However, a major regulator of cellular
cholesterol and phospholipid homeostasis is the ABCA1 trans-
porter. ABCA1 is an integral trans-membrane protein that moves
phospholipids and free cholesterol across the cell membrane to
combine them with lipid-free ApoA1, which is also synthesised in
the liver, to form nascent HDL particles [25,26]. ABCA1 is highly
expressed in the liver and tissue macrophages. Nevertheless, the
liver ABCA1 pathway appears to generate most (70–80%) plasma
HDL [27]. ABCA1 exports cholesterol exclusively at the cell
surface [28]. Free cholesterol in nascent HDL particles is
subsequently converted to cholesterol esters by the lecithin:cho-
lesterol acyltransferase (LCAT). The absence of functional ABCA1
is the feature of Tangier disease, characterized by a severely
impaired lipidation of ApoA1 via the ABCA1 pathway, and very
low blood levels of HDL [29].
The modulation of intracellular and membrane cholesterol
homeostasis has dramatic effects on the early stages of several viral
infections [30,31]. Thus, we hypothesised that stimulation of the
ABCA1-mediated cholesterol efflux may influence the course of
HCV infection. We provide here the first evidence that
pharmacological stimulation of the ABCA1 pathway efficiently
inhibits virus-cell entry and decreases virus infection levels in the
HCVcc model and in primary human hepatocytes. Our findings
highlight ABCA1 as a novel potential target for HCV strategies.
Materials and Methods
Cell Infection with HCVcc
The JFH1 HCV strain (genotype 2a) was kindly provided by T.
Wakita. Infectious HCV virions were generated as described [32].
Huh7.5 hepatoma cells (kindly provided by C. Rice) were grown
as described [33] and were infected with the virus preparation at
105 ffu/ml (focus forming units per millilitre), at an MOI= 0.001–
0.01 for 2 h at 37uC. They were then grown further for the
indicated time at 37uC.
Primary human hepatocytes were isolated from two adult liver
donors after resection for medical reasons and infected with
HCVcc as previously described [34].
To culture liver tissue slices, human samples were obtained from
adult HCV, HBV and HIV seronegative patients who underwent
liver resection in the absence of underlying liver disease. These
samples were infected with HCVcc [35].
Ethics Statement
The French Ministry of Research and Higher Education
delivered the authorization NuDC-2008-531 to collect hepatic
resection samples from the digestive surgery department and to
isolate primary human hepatocytes. The experiments on the
human liver slices were performed on surgical samples (from
resections of liver metastases), which are considered as ‘‘biological
waste’’ and require neither patient nor institutional review board
approval. The local Ethics Committee of the Cochin Hospital in
Paris, France, approved these experiments.
Stimulation of ABCA1 Expression
Cell toxicity of LXR agonists GW3965 and TO901317 (Sigma)
was determined using the CellTiter-Glo luminescent Cell Viability
Assay (Promega). To stimulate ABCA1 expression, Huh7.5 cells or
primary hepatocytes were treated with 1–10 mM concentrations of
the drugs (diluted in DMSO) for 24 h before infection, or with
corresponding dilutions of DMSO. Cells were grown for the
indicated time and ABCA1 mRNA levels were analysed by qRT-
PCR. ABCA1 protein was determined by Western Blot and
quantified using the Odyssey Infrared Imaging system. ABCA1
function was measured using cholesterol efflux assay.
Quantitative RT-PCR (qRT-PCR)
HCV RNA was determined as previously described [33]. For
measurement of the ABCA1 mRNA, 59-
CCTGACCGGGTTGTTCCC-39 and 59-
TTCTGCCGGATGGTGCTC-39 primers were used for ampli-
fication and 59-ACATCCTGGGAAAAGACATTCGCTCTGA-
39 (Eurogentec) served as an internal probe. The results were
normalized by quantification of HPRT1 or GADPH cellular genes
using the HPRT1 Taqman Gene Expression Assay (Life
Technology Applied Biosystems) or the GAPDH Control Kit
(Eurogentec), respectively.
All assays were performed at least in quadruplicate. Error bars
on the histograms represent standard deviation of the mean values
from at least quadruplicates.
Cholesterol Efflux Assay
Control or drug-treated Huh7.5 cells were cholesterol-loaded
using 1 mCi/mL [3H] cholesterol-labelled SVF (10%) for 24 h in
DMEM medium. Cells were then incubated in serum-free
medium containing 0.2% BSA with or without 1 mM GW3965
ABCA1 and HCV Infection
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for 16 h. Cellular cholesterol efflux to 25 mg/mL lipid-free ApoA1
(Sigma) was assayed in serum-free medium containing 0.2% BSA
for a 4 h chase period, then culture medium was harvested and
cleared by centrifugation. Cell-associated radioactivity was deter-
mined by extraction in hexane-isopropanol (3:2), evaporation of
the solvent and liquid scintillation counting (Wallac Trilux 1450
Microbeta). The percentage of cholesterol efflux was calculated
according to the formula = 1006(medium cpm)/(medium cpm+
cell cpm). ApoA1-specific cholesterol efflux was determined by
subtracting the cholesterol efflux that occurred in apoA-I-free
medium.
ABCA1 Silencing
Stealth siRNA targeting three different zones of human ABCA1
gene (Life Technologies Applied Biosystems) were used. Huh7.5
cells were transfected with 25 nM ABCA1-specific siRNA or with
25 nM scrambled siRNA (Eurogentec), using the RNAi Max
reagent (Invitrogen). At 24 h and 48 h after transfection ABCA1
mRNA levels were determined by qRT-PCR, ABCA1 protein by
Western Blot and ABCA1 function by cholesterol efflux assay.
Cell–to-cell Fusion Assay
The assay was performed as described previously [36].
HEK293T kidney cells (ATCC CRL-1573) were cultured in
DMEM supplemented with 10% FBS, 1% non-essential amino
acids, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells
(2.56105 cells/well seeded in 35 mm 6-well tissue culture dishes
24 h before transfection) were co-transfected using the calcium
phosphate reagent with a plasmid encoding HCV envelope
proteins (H77 strain genotype 1a) or Chikungunya envelope
encoding-plasmid (ChikV) issued from ChikV E3E1E2 plasmid
from the Re´union infectious clone and with an HIV-1 LTR
(long terminal repeat) luciferase reporter plasmid (kindly
provided by Francoise Bex). After 12 h, transfected HEK293T
cells were detached with 0.53 mM EDTA (Invitrogen) and co-
cultured (56104 cells/well) with Huh-7-Tat indicator cells
(56104 cells/well). Co-cultured cells were then incubated with
1 mM of GW3965 or with DMSO. After 24 h, the cells were
washed with serum-free DMEM, incubated for 3 min in either
pH 7 or pH 5 buffer, (containing 130 mM NaCl, 15 mM
sodium citrate, 10 mM MES and 5 mM Hepes), then washed
with serum-free DMEM. Cells were next incubated with 1 mM
of GW3965 or with DMSO for 48 h. Luciferase activity was
measured using a luciferase assay kit (Promega). The experi-
ments were performed several times and results interpreted
using student t-test.
Analysis of Green Fluorescent Protein-Folate Receptor
Cell Distribution by Fluorescence Microscopy
Huh7.5 cells were transfected with 0.5 mg of DNA encoding a
fusion protein, where GFP is fused to the Glycosylphosphatidyl-
inositol-anchor attachment signal of folate receptor (GFP-FR)
[37,38]. Four hours post-transfection cells were treated with 1 mM
GW3965 or with a drug solvent (DMSO) that was renewed at 24 h
post-transfection. Two days after transfection cells were fixed with
4% PFA containing 0.2% glutaraldehyde. Fluorescence of GFP-
FR was visualised with a Zeiss Axioplan 2 microscope at 488 nm
(x63 objective).
Quantification of mRNA of Genes Involved in Lipid
Metabolism
Total RNA was extracted using the NucleoSpin RNA II kit
(Macherey-Nagel). Reverse transcription and real time qPCR
assays were performed as previously described [39] and mRNA
levels were normalized compared to those of housekeeping
genes (18S, human delta-aminolevulinate synthetase, human
alpha-tubulin, human heat shock protein 90 kDa alpha and
human hypoxanthine phosphoribosyltransferase 1). Data were
expressed as a fold-change in mRNA expression relative to
control values.
Determination of Intracellular Lipids
Quantification of total cellular triglyceride mass was performed
as previously described [40]. Free and esterified cholesterol mass
was quantified using the Amplex Red cholesterol assay kit
(Molecular Probes) [41].
Cholesterol Replenishment
Control or GW3965-treated Huh7.5 cells were incubated with
20 mg/ml cholesterol:Methyl b Cyclodextrine D (MbCD) com-
plexes (Sigma) for 1 h at 37uC. Cells were extensively washed and
analysed for their lipid/cholesterol content or infected with HCV.
Virus Binding Assay
GW3965 - treated or control Huh7.5 cells were washed with
cold medium and incubated with 100 ml of HCV preparation for
2 h at 4uC. Cells were extensively washed to remove the unbound
virus, total RNA was extracted and HCV RNA was determined by
qRT-PCR.
HCV Replicon
Huh7 cells harbouring the HCV JFH-1 sub-genomic replicon
were kindly provided by J. McLauchlan and grown as described
[42]. Replicon cells were treated with 1 mM GW3965 diluted in
DMSO for 72 h. Every 24 h the cell culture medium was replaced
by fresh medium that contained the drug at the same concentra-
tion. As a control, replicon cells were treated in the same way with
0.66 mM cyclosporine A (CsA, Sigma) a known HCV replication
inhibitor. Total RNA was extracted from cells every 24 h and
HCV RNA assessed by qRT-PCR.
Determination of HCV Infectivity
An infectivity assay was performed using Huh7.5 cells seeded in
96-well plates and inoculated with serially (ten-fold) diluted
HCVcc preparations. After 72 h cells were fixed with 4%
paraformaldehyde for 30 min at room temperature and the
infected foci were visualized by In-Cell Western assay using
human anti-HCV serum and DyLightTM 800 labelled goat anti-
Human IgG (KPL, Inc., MD, USA). Fluorescent foci were
detected in infected cells using the Odyssey Infrared Imaging
System (LI-COR Biosciences, NE, USA). Infectivity was expressed
as focus forming units/ml (ffu/ml).
Ultracentrifugation through an Iodixanol Gradient
Centrifugation was carried out as previously described [33]. A
discontinuous 5–50% iodixanol density gradient (OptiPrep) was
prepared in a buffer that contained 40 mM HEPES, 270 mM
NaCl and 10 mM KCl. The supernatants from infected cells were
concentrated using a Vivaspin concentrator (Vivascience) and
centrifuged in the gradient for 24 h at 38,000 rpm at 4uC in an
SW41Ti rotor of a Beckman ultracentrifuge. Fractions (450 ml)
were collected and analysed for the presence of HCV RNA by
qRT-PCR. HCV core protein, Apolipoprotein E (ApoE) and
Apolipoprotein B (Apo B) were determined by ELISA assays
(Mabtech AB, France), and HCV core was quantified by the
ABCA1 and HCV Infection
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Chemiluminescent Microparticle Immunoassay (Architect,
HCVAg; Abbott Lbs, USA).
Flow Cytometry
Drug- or solvent -treated Huh7.5 cells were grown in 6-well
plates to obtain 16106 cells/well. Cells were harvested by
incubation with Versene, followed by centrifugation and re-
suspended in a FACS buffer containing 1% BSA and 0.01%
Azide in phosphate-buffered saline (PBS). Cells were then
incubated with primary antibodies: monoclonal antibody anti-
CD81, rabbit anti-LDL-R antibody (Abcam, Cambridge, UK),
or rabbit polyclonal anti SR-BI (kindly provided by T. Huby)
for 30 min at 4uC, washed and incubated with APC-conjugated
anti-mouse or FITC-conjugated anti-rabbit antibody (BD
Pharmigen) for 30 min at 4uC. Cells stained with only
secondary antibodies were used as negative controls. Cells were
washed with FACS buffer, fixed with 1% paraformaldehyde and
analysed by FACSCalibur (BD Bioscience) using FlowJo
software (Three stars). A total of 25,000 to 50,000 events were
collected per sample.
Duolink Proximity Ligation Assay
Duolink assay (Sigma-Aldrich) based on proximity ligation
technology (PLA) was used to determine the co-localisation of
HCV receptors CLDN1 and SR-BI relative to CD81 (,40 nm) in
drug-treated or solvent-treated cells. Monoclonal antibodies to CD
81 (Abcam, Cambridge, UK), and rabbit anti-CLDN1 (Abcam,
Cambridge, UK) and rabbit polyclonal anti SR-BI (kindly
provided by T. Huby) were used in the assay. After signal
amplification the slides were examined using fluorescence Zeiss
axioplan 2 microscope (x63 objective) at 598 nm. The obtained
images were quantitatively analysed using Duolink Image Tool
software.
Determination of SR-BI Function
To investigate cholesterol efflux to HDL via the human
Scavenger Class B type I Receptor (SR-BI) pathway, SR-BI gene
expression was silenced with 50 nM SR-BI specific siRNA.
Alternatively 50 nM control siRNA was employed. After 24 h
incubation at 37uC, SR-BI knocked-down and control cells were
labelled with [3H] cholesterol in the presence or absence of 1 mM
GW3965. Cholesterol efflux to 50 mg/mL HDL isolated from
normolipidemic plasma [43] was assayed during a 4 h chase
period in the presence or absence of 1 mM GW3965.
Western Blot
Cells were lysed with a buffer containing 20 mM Tris-HCl
pH 7.5, 150 mM NaCl, 10% glycerol and 1% Triton X-100. After
freeze-thawing and sonication, samples of 50 mg total protein were
heated for 10 min at 95uC in a sample buffer containing SDS and
reducing agent and subjected to electrophoresis in 3–8% Tris-
Acetate polyacrylamide. Proteins were then transferred to
nitrocellulose membranes and blocked with 5% skim milk in
PBS containing 0.1% Tween 20. Blots were then reacted with
rabbit anti-CLD1, rabbit anti-OCLN, rabbit anti-pan Cadherin
(Abcam Cambridge, UK); rabbit anti-ABCA1 (Novus Bio); or
mouse anti-NPC1 (Santa Cruz) as primary antibodies, followed by
DyLight 680 conjugated anti-Mouse IgG or DyLight 800
conjugated anti-Rabbit IgG (WWR, France). Blots were quantified
using the Odyssey Infrared Imaging System (LI-COR Biosciences,
NE, USA).
Results
GW3965 Up-regulates ABCA1 Gene Expression and
Cholesterol Efflux Function
Liver X receptors (LXRa and LXRb) are ligand-activated
transcription factors, which act as cholesterol sensors and control
hepatic cholesterol and fatty acid homeostasis [44,45]. GW3965 is
a synthetic compound (LXR agonist) that up-regulates ABCA1
[46]. No appreciable cytotoxicity of the drug for Huh 7.5 cells was
observed at a concentration range of 0.08–10 mM (Figure 1A).
Treatment of Huh7.5 cells with 1 mMGW3965 for 24 h increased
ABCA1 mRNA levels up to 5-fold (Figure 1B). Up-regulation of
the ABCA1 gene expression raised ABCA1 protein production
(Figure 1C) and enhanced free cholesterol efflux to ApoA1
(Figure 1D). Studies of the kinetics of ABCA1 stimulation showed
progressive increase of ABCA1 gene expression until a plateau was
reached after 16–24 h (Figure 1E), and gradually augmented
cholesterol efflux to ApoA1 (Figure 1F). Thus, 24 h of treatment of
cells with the drug was used in further experiments to raise
ABCA1 levels.
Stimulation of ABCA1 Inhibits HCV Infection
Infection with HCV did not modify ABCA1 gene expression in
Huh7.5 cells during 72 h cell growth (not shown). To assess
whether stimulation of ABCA1 expression and physiological
function would influence the HCV life cycle, Huh7.5 cells were
pre-treated with 1 mM GW3965 for 24 h to raise ABCA1 levels
and then infected with HCV. Up-regulation of ABCA1 decreased
intracellular HCV RNA levels (Figure 2A) at 24 h post infection
and significantly reduced the virus production. This was evidenced
by the decrease of HCV RNA in the cell supernatant (Figure 2B),
which corroborated with a decrease of the concentration of HCV
core antigen by 100 fold (not shown). Continuous GW3965
treatment for 7 days substantially reduced the amount of HCV
RNA detected in the cell supernatant in parallel with the increase
of ABCA1 expression in virus-producing cells (Figure 2C).
TO901317, another synthetic LXR agonist known to be a
potent inducer of ABCA1 [47,48], inhibited HCV infection to the
same extent as GW3965 did (not shown). No further decrease of
infection was obtained when the two drugs were used simulta-
neously or in higher concentrations (up to 50 mM). These
observations suggested that GW3965 and TO901317 inhibited
HCV infection by similar mechanisms.
ABCA1 Plays a Key Role in the Inhibition of HCV Infection
Activation of LXRs by their agonists such as GW3965 or
TO901317 enhances ABCA1 gene expression but also may affect
the expression of other genes that regulate lipid metabolic
pathways [45]. Indeed, transcriptomic profiling of Huh7.5 cells
treated with GW3965 revealed modified mRNA levels of several
genes involved in hepatic lipid metabolism: increased mRNA
levels of ABCA1 and ABCG1, nuclear LXRa (but not the LXRb
receptor), a sterol regulatory element binding protein-1c (SREBP-
1c), fatty acid synthase (FAS) and phospholipid transfer protein
(PLTP). The treatment had no significant effect on mRNA levels
of fatty acid transporter CD36 and ApoA1 mRNA (Figure 3).
We therefore investigated whether ABCA1 activation was
responsible for the inhibition of HCV infection by knocking down
the ABCA1 gene. We used three siRNAs that target different
regions of ABCA1 gene or a mixture of them to reduce ABCA1
expression. All approaches gave similar rates of ABCA1 reduction
(60–80%) as compared to scrambled siRNA. Knocking down of
the ABCA1 gene in Huh7.5 cells (Figure 4A) significantly reduced
the production of the ABCA1 protein (Figure 4B) and impaired
ABCA1 and HCV Infection
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cholesterol efflux to ApoA1 (Figure 4C) as compared to a control
siRNA.
To assess whether ABCA1 stimulation was responsible for the
inhibition of infection, Huh7.5 cells were transfected with ABCA1
siRNA to knock down its expression (or with scrambled siRNA)
and then treated for 24 h with 1 mM GW3965 or solvent. Cells
were subsequently infected with HCV and infection levels were
evaluated by measuring intracellular HCV RNA at 24 h after
infection. Consistent with the requirement of ABCA1 stimulation
to induce the inhibitory effect by GW3965 treatment, the drug did
not decrease infection levels in ABCA1-silenced cells (Figure 4D).
These results provided evidence that the inhibition of infection
was mediated by the over-expressed and fully functional ABCA1.
GW3695 Treatment Inhibits HCV Cell Entry, but does not
Impair other Steps of the Virus-cell Cycle
To determine which step of the HCV infection was affected by
GW3965 treatment, we analysed the kinetics of activity of this
compound by adding the drug at different time points of the virus
cycle (depicted in Figure 5). When cells were pre-treated with
GW3695 before virus inoculation, and the drug was maintained
Figure 1. GW3965 treatment up-regulates ABCA1 expression
and its cholesterol efflux function. (A) Cell toxicity of GW3965.
Huh7.5 cells were cultured in the presence of indicated concentrations
of the drug for 24 h. The luminescent signal is expressed in
luminescence units (RLU). (B) Up-regulation of ABCA1 mRNA expression
by GW3695 treatment. Huh7.5 cells were treated for 24 h with 1 mM
GW3695 or drug solvent (DMSO). Then ABCA1 mRNA was determined
by qRT-PCR. (C) ABCA1 protein production in drug-stimulated Huh7.5
cells. Cells were treated for 24 h with 1 mM GW3965 and analysed by
Western blot (shown in the insert). Protein content in the ABCA1 band
(220 kDA) in GW3965-(GW), and DMSO-(solv) treated cells was
quantified relative to the calnexin band using the Odyssey Infrared
Imaging System. (D) GW3965 stimulation promotes ABCA1-mediated
cholesterol efflux to ApoA1. Huh7.5 cells were labelled with [3H]
cholesterol then incubated with GW3965 or drug solvent. ABCA1-
dependent [3H] cholesterol efflux was assayed by comparing cell-
associated and free radioactivity. (E) Kinetics of ABCA1 gene expression
following stimulation of cells with GW3965. Huh7.5 cells were treated
with 1 mM GW3965 for the indicated time and ABCA1 mRNA was
determined by qRT-PCR. Results were expressed as relative values
compared to ABCA1 expression in cells treated with drug solvent. (F)
Kinetics of cholesterol efflux in cells stimulated with GW3965. Huh7.5
cells were labelled with [3H] cholesterol for 24 h, and incubated for an
additional 16 h with 1 mM GW3965 or drug solvent. ABCA1-dependent
[3H] cholesterol efflux was assayed in the presence of ApoA1 and either
GW3965 or solvent for the indicated period of time.
doi:10.1371/journal.pone.0092140.g001
Figure 2. Stimulation of ABCA1 inhibits HCV infection. (A)
Reduction of intracellular HCV RNA levels in cells that over-express
ABCA1. Huh7.5 cells were pre-treated with 1 mM GW3965 then infected
with HCV. Cells were grown for a further 24 h, total RNA was extracted
and intracellular HCV RNA was determined by qRT-PCR. Results are
expressed as the percentage of HCV RNA relative to that in cells treated
with drug solvent prior to infection. (B) Decrease of HCV RNA levels in
the supernatant collected from drug-stimulated cells. Huh7.5 cells were
pre-treated with 1 mM GW3965 then infected with HCV. After a further
72 h, HCV-RNA in the culture medium was determined by qRT-PCR.
Results are expressed as the percentage of HCV RNA secreted from
drug-treated cells compared to solvent-treated cells. (C) Effect of
GW3965 treatment on long-term HCV infection. Huh 7.5 cells were pre-
treated with 1 mM GW3965, infected with HCV and grown for up to 7
days in the presence of the drug. ABCA1 mRNA was determined by qRT-
PCR every 24 h and results are expressed as a fold-increase of ABCA1
mRNA compared to solvent-treated cells (grey bars). HCV RNA in the
cell supernatant was measured at the same time points by qRT-PCR
(line curves for GW3965 treated [filled triangles] or control [filled
squares] cells) and is expressed in International Units (IU).
doi:10.1371/journal.pone.0092140.g002
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during infection, intracellular HCV RNA levels decreased at 24 h,
48 h or 72 h post-infection (Figure 5). No inhibition of infection
was observed when the drug was added concomitantly with the
virus, without cell pre-incubation. These observations provided
evidence that GW3965 had no direct detrimental effect on virus
structure and infectivity, membrane composition, or fusion events
and suggested that raising ABCA1 levels was required to affect
infection. Furthermore, no inhibitory effect was noted when the
drug was applied at different time points post-infection (Figure 5)
implying that pre-treatment of cells with the drug stimulating
ABCA1 impaired virus entry, but did not affect later steps of the
virus life cycle.
To assess whether the treatment influenced the initial virus
attachment to the cell surface, or later steps in virus-cell entry,
Huh7.5 cells were pre-treated with GW3965 for 24 h to stimulate
ABCA1 expression. The virus was then added and incubated with
cells for 2 h at 4uC. After washings, the cell-bound HCV was
quantified by qRT-PCR. These experiments showed that over-
expression of ABCA1 after GW3965 treatment (Figure 6A) did not
affect virus binding to the cell surface (Figure 6B). Hence, the
inhibitory effect induced by over-expressed ABCA1 concerned
virus entry events after the binding step.
No inhibition of infection was observed when the drug was
added at several time points (2 h, 4 h and 6 h) after infection
(Figure 5), suggesting that ABCA1 stimulation does not impair
virus replication. This was further confirmed using the sub-
genomic HCV replicon model, which permits studies of HCV
replication mechanisms without the expression of HCV structural
proteins. HCV RNA replication was not affected by GW3965
treatment for 72 h (Figure 6C), but was inhibited, in a time
dependent manner by cyclosporine A, known inhibitor of HCV
replication, used here as a control (Figure 6D).
Increased ABCA1 expression did not affect mechanisms of
assembly/secretion of virus particles. Indeed, when infected cells
were continuously treated with GW3965 and the cell medium
collected every 24 h (to prevent the effect of ABCA1 stimulation
Figure 3. GW3695 treatment modulates expression of genes involved in lipid metabolism. Huh7.5 cells were treated with 1 mM GW3695.
Total RNA was extracted from cells and the mRNA levels corresponding to several genes regulating lipoprotein metabolism: ABCA1, ABCG1, nuclear
LXRa and LXRb receptors, a sterol regulatory element binding protein-1c (SREBP-1c), fatty acid synthase (FAS) and phospholipid transfer protein
(PLTP), CD36 and ApoA1 were determined by qRT-PCR. The results were normalized to housekeeping genes and compared to the levels of
corresponding mRNAs in solvent-treated cells.
doi:10.1371/journal.pone.0092140.g003
ABCA1 and HCV Infection
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92140
on virus-cell entry) no difference in concentration of HCV core
antigen was observed in supernatants collected at 48 h or 72 h
post infection, from drug-treated compared to non-treated cells
(Figure 6E). The infectivity of virus particles in these cell
supernatants was also very similar (Figure 6F).
Collectively, these data demonstrated that stimulation of
ABCA1-mediated cholesterol efflux inhibited cell entry step, after
virus attachment to the cell surface. However the treatment did
not affect other steps of the HCV life cycle and the infectivity of
secreted virus particles was unchanged. Accordingly, a decrease of
virus production in ABCA1 over-expressing cells was a conse-
quence of reduced virus-cell entry.
Analysis of HCV Particles Produced in GW3965-treated
Cells
The increased cellular cholesterol efflux in GW3965 cells did
not affect levels of ApoB secreted to the cell supernatant (data not
shown) and only slightly affected the total (Figure 7A) and free
cholesterol (Figure 7B) content in Huh7.5 cell cultures. Instead, the
treatment reduced the concentration of cholesteryl esters
(Figure 7C) and increased cellular triglycerides (Figure 7D), as a
result of well-known stimulation of lipogenesis via LXRs. These
changes might potentially affect physical characteristics of the virus
particles produced in drug-treated cells.
We therefore investigated the properties of virus particles
produced in cells continuously stimulated with GW3965 by
centrifugation in a discontinuous 5–50% iodixanol gradient. Since
significantly less virus was produced and secreted from drug-
stimulated compared to non-stimulated cells (shown in Figure 2B)
the cell culture medium was concentrated before ultracentrifuga-
tion. Nevertheless, in spite of quantitative differences in the levels
of virus production, overall properties of viruses produced in the
presence or absence of the drug were very similar (Figure 8 A and
B). In both gradients HCV RNA was detected in two peaks at a
density of 1.1 and 1.12 g/ml. The low-density virus peak co-
localised with ApoB and partially with HCV core antigen, which
was more abundant in the high density RNA peak.
Thus, stimulation of ABCA1 expression upon GW3965
treatment did not significantly change either infectivity (shown in
Figure 6F) or physicochemical properties of the virus particles
produced (Figure 8A and B) regardless of the influence of ABCA1
Figure 4. ABCA1 plays a key role in the inhibition of HCV infection. (A) Silencing of ABCA1. Huh7.5 cells were transfected with siRNA that
targets ABCA1, or with a control siRNA. Total RNA was extracted after 48 h and ABCA1 mRNA determined by qRT-PCR. Results are expressed as the
percentage of ABCA1 mRNA in cells transfected with siRNA targeting ABCA1 relative to mRNA levels in control cells. (B) Decreased ABCA1 protein
synthesis in ABCA1-knocked-down cells. Huh7.5 cells were transfected with ABCA1-specific siRNA as above. Cell lysates were subjected to Western
blot analysis. Staining of the ABCA1 protein with specific antibodies is shown in the insert. Results are expressed as the ABCA1 protein content in
ABCA1-siRNA transfected cells relative to that in control siRNA transfected cells, normalized to calnexin (quantification using the Odyssey Infrared
Imaging System). (C) Loss of cholesterol efflux function in ABCA1-silenced cells. Huh7.5 cells were transfected with siRNA that targets ABCA1 or with
control siRNA. ABCA1-dependent [3H] cholesterol efflux was assayed in the presence of ApoA1. Results are expressed as percentage of cholesterol
efflux to ApoA1 in ABCA1 knocked-down cells relative to control si-RNA transfected cells. (D) Silencing of ABCA1 antagonizes GW3965-mediated
inhibition of HCV infection. The expression of ABCA1 was reduced by transfection with ABCA1-specific siRNA (as in A) and cells were treated with
1 mM GW3965, infected and grown for a further 24 h. HCV RNA was determined by qRT-PCR. Results are expressed as the percentage of HCV RNA in
drug-treated (GW3965) cells or ABCA1-silenced and subsequently GW3965-treated cells (siABCA1+GW3965), compared to solvent-treated cells.
doi:10.1371/journal.pone.0092140.g004
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overexpression on the levels of HCV infection and virus
production.
GW3695 does not Change the Expression of HCV
Receptors
We further assessed whether the inhibition of HCV cell entry by
ABCA1 over-expression was associated with changes in expression
of major HCV receptors. Flow cytometry analyses demonstrated
that GW3965 stimulation did not change the global expression
levels of CD81, SR-BI, and LDL-R in Huh7.5 cells (Figure 9A).
Equally, Western Blot analyses (Figure 9B) confirmed that the
expression of NPC1, CLDN1 and OCLN were not modified by
the treatment. In addition, ABCA1 stimulation did not modify the
cell surface distribution of CD81 relative to SR-BI, or CD81
relative to CLDN1, which interact at the plasma membrane
forming HCV receptor complexes [22,49]. The distance between
these pairs of receptors was determined to be ,40 nm by the
Duolink Proximity Ligation Assay (data not shown). Furthermore,
ABCA1 over-expression did not reduce SR-BI specific cholesterol
transfer activity to HDL that is required for HCV cell entry [50]
(data not shown).
Hence, impaired HCV entry following ABCA1 over-expression
was not due to changes in the overall expression of major HCV
receptor molecules, or distribution of receptors known to co-
localise. It was equally not due to reduced SR-BI cholesterol
transfer activity to HDL.
Stimulation of ABCA1 Affects Virus-cell Fusion
ABCA1 exerts an important influence on the plasma membrane
structure, moving cholesterol within the membrane, leading to
disorganisation of cholesterol-rich raft domains [51,52,53,54,55].
These changes might impair virus-cell fusion mechanisms. Using a
previously developed assay [36], we found that indeed increased
ABCA1 expression upon GW3965 stimulation inhibited cell fusion
induced by HCV envelope proteins (*p,0.03), whereas Chikun-
gunya envelope-induced fusion (a control) was not significantly
affected (Figure 9C).
These observations suggested the impact of the increased
cholesterol efflux on specific membrane rearrangements required
for HCV-induced fusion.
GW3965 Treatment Affects the Organization of
Cholesterol Enriched Membrane Microdomains
ABCA1 disorganises cholesterol-rich raft microdomains and
redistributes cholesterol/sphingolipids from raft to non-raft
domains making it available for ApoA1 and facilitating HDL
production [51,52,53,54,55] Supplying cells that over-express
ABCA1 with exogenous cholesterol should redistribute membrane
cholesterol between these domains and thus inverse the effect of
ABCA1 [56].
To assess whether ABCA1-stimulated inhibition of HCV entry
might be reversed by the cholesterol supply, we incubated cells
that over-expressed ABCA1 with cholesterol/MbCD complexes.
Cholesterol/MbCD–treatment increased total cellular cholesterol
content (Figure 9D) and completely reversed the inhibitory effect
of ABCA1 stimulation on HCV cell entry (Figure 9E).
These data suggested that the increased cholesterol efflux via
ABCA1 induced remodelling of the cholesterol-rich lipid raft
microdomains and accordingly affected virus-induced fusion. The
inhibitory effect could be reversed by an exogenous cholesterol
supply, providing evidence that restriction of HCV infection was
induced by changes of cholesterol content/distribution in mem-
brane regions essential for virus-cell entry.
To confirm that indeed GW3965 treatment affected cholesterol-
enriched membrane microdomains (lipid rafts) we analysed the
plasma membrane distribution of a raft-associated Glycosylpho-
sphatidyl-inositol-anchor attachment signal of the folate receptor
(GFP-FR). Glycosylphosphatidyl-inositol (GPI)-anchored proteins
are cholesterol-dependent for their plasma membrane organiza-
tion and thus can be used as lipid raft markers [37,57].
Fluorescence microscopy analysis demonstrated that, while in
untreated cells GFP-FR was homogenously distributed at the
plasma membrane, in GW3965-treated cells GFP-FR expression
was drastically different from the control (Figure 9 F and G). Thus,
ABCA1 stimulation affected the organization of cholesterol
enriched membrane microdomains.
GW3965 Inhibits HCV Infection of Primary Human
Hepatocytes
Since Huh7.5 cells currently used as a model for studies of HCV
infection have several differences in lipid metabolism compared to
primary human hepatocytes, we investigated the effect of ABCA1
up-regulation on HCV infection of human hepatocytes in primary
culture [34] or HCV infection of human liver slices [35], the two
available models that are permissive for a full HCV life cycle and
display normal lipid/lipoprotein metabolic pathways.
Figure 5. Up-regulation of ABCA1 inhibits HCV cell entry. The
effect of GW3965 on the HCV cell cycle was analysed by adding the
drug at different time points. A flow-chart is depicted in the upper
panel of the graph. RNA in Huh7.5 cells infected in the presence of
DMSO is shown in (a); that in cells pre-treated for 24 h with 1 mM
GW3965 and infected in the presence of the drug are shown in (b), (c)
and (d); results for cells treated with GW3965 during virus inoculation
without pre-treatment are shown in (e); those of assays where the drug
was added at 2 h, 4 h, or 6 h post-infection are presented in (f), (g) and
(h) respectively. For each experiment cells were incubated for the
indicated time period after infection (IV). The efficiency of infection was
expressed as intracellular HCV RNA measured by qRT-PCR as a per cent
of the control (a).
doi:10.1371/journal.pone.0092140.g005
ABCA1 and HCV Infection
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e92140
First, hepatocytes obtained from two liver donors were pre-
treated with various concentrations of GW3965 (2–10 mM). Cells
were then infected with HCVcc and grown for 24 h or 48 h and
HCV RNA was determined by qRT-PCR. As shown in Figure 10
(A–B) ABCA1 up-regulation was associated with a dose dependent
decrease of intracellular HCV RNA levels.
A substantial inhibition of HCV infection was also observed in
the model of primary human liver slices cultures. Cultures of
human liver slices were established with differentiation status and
were treated with 5 mM and 10 mM concentrations of GW3965 or
with drug solvent, for 24 h before infection with HCVcc. These
drug concentrations were selected on the basis of results showing
Figure 6. Stimulation of ABCA1 has no impact on HCV cell attachment, HCV RNA replication, assembly/secretion or infectivity of
virus particles. (A–B) GW3965 treatment does not affect HCV cell attachment. Huh7.5 cells were pre-treated for 24 h with 1 mM GW3965, to raise
ABCA1 levels and tested for their capacity to attach HCV using a ‘‘binding assay’’. (A) HCV RNA attached to drug pre-treated cells (GW3965) is
expressed as per cent relative to HCV RNA attached to cells treated with DMSO (solvent). (B) ABCA1 mRNA levels were determined by corresponding
qRT-PCR and expressed in arbitrary units. (C) Stimulation of ABCA1 does not affect HCV RNA replication. Huh7 cells that express the sub-genomic
replicon were incubated for 72 h with 1 mM GW3965 or with the equivalent concentration of drug solvent. HCV RNA was quantified by qRT-PCR in
drug-treated cells relative to HCV RNA in control replicon cells grown in the presence of drug solvent. (D) HCV RNA replication is inhibited by CsA
(control for C). Replicon cells were grown in medium containing 0.67 mM CsA or drug solvent (EtOH) for 72 h. HCV RNA was measured by qRT-PCR
every 24 h and results were expressed as the percentage of HCV RNA in drug treated cells relative to HCV RNA content in cells grown in the presence
of drug solvent. (E) ABCA1 up-regulation does not affect virus particle assembly/secretion. Huh7.5 cells were infected with HCV and 1 mM GW3965
was applied to cells 2 h post-infection. Every 24 h drug was replenished. HCV core antigen secreted to the cell supernatant was quantified at 48 h
and 72 h post infection. Results were normalized with respect to the total protein content in the supernatant and are expressed in fmol/L. (F)
Infectivity of virus particles secreted to the cell supernatant from cells treated according to the procedure described in (E) and determined using In
Cell Western Blot assay. Results are expressed in ffu/ml.
doi:10.1371/journal.pone.0092140.g006
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that they were not toxic for cells and were required to raise
ABCA1 levels.
HCV RNA levels decreased at least by two logs in drug-treated
cells, compared to non-treated cells, while ABCA1 gene expression
concomitantly increased 2.5 fold over the time course of the
experiment (Figure 10 C and D).
Altogether these data provided evidence that pharmacological
stimulation of ABCA1 expression efficiently inhibited HCV
infection of primary hepatocytes.
Discussion
In this work, we provide the first demonstration that pharma-
cological stimulation of ABCA1 gene expression and its cholesterol
efflux function with the LXR agonist GW3965 impairs HCV
infection, acting on virus protein mediated-host cell fusion. The
inhibitory mechanism was associated with re-organisation of
cholesterol-rich membrane microdomains (lipid rafts). Stimulation
of ABCA1 expression also efficiently inhibited infection of human
hepatocytes in primary culture (the natural HCV target cell) and
isolated human liver slices.
LXRs are ligand-activated transcription factors, which maintain
cholesterol homeostasis. LXR agonists increase ABCA1 expression
but also modulate several other genes that regulate lipid metabolic
pathways [58,59]. Indeed, we found that GW3965 affected the
expression of several genes involved in hepatic lipid metabolism.
Nevertheless, silencing of the ABCA1 gene and reducing its
protein expression and specific efflux function reversed the
inhibitory effect of GW3965, supporting the key role of ABCA1
in the inhibition of HCV infection.
In hepatocytes, the specific cholesterol efflux function and
nascent HDL formation only depends on ABCA1, whereas
ABCG1, another cholesterol transporter, acts in synergy with
ABCA1 to promote cellular cholesterol efflux to preformed
nascent HDL particles. SR-BI, one of the main HCV receptors,
contributes neither to cholesterol efflux to ApoA1 nor to HDL
formation [60]. Thus the specific cholesterol efflux function to Apo
A1 activated by the treatment with GW3965 or TO90317 was due
to ABCA1 activity.
Stimulation of ABCA1 by these drugs impaired HCV cell entry
by acting on virus protein-mediated cell fusion, presumably
blocking virus nucleocapsid release into the cytosol. GW3965
did not directly affect the virus particle or cell membrane structure,
since adding the drug during virus inoculation did not reduce its
infectivity. Instead, inhibition of infection required ABCA1 over-
expression and activation of its function during several hours.
GW3965 did not influence either virus binding to the cell surface
or HCV RNA replication.
Up-regulation of ABCA1-mediated hepatic cholesterol efflux
might decrease hepatic VLDL secretion [61]. In our study
GW3965 treatment did not affect either levels of ApoA1 in the
cell supernatant, or virus assembly/secretion mechanisms. It did
not change physicochemical properties or infectivity of the virus
particles produced in drug-treated cells. Thus the decrease in
HCV production and secretion was due to impaired virus-cell
entry.
The inhibition of HCV cell entry via stimulation of the ABCA1
pathway was not associated with changes in overall expression of
HCV receptors: LDL-R [8], HSPG [62], CD81 [63], SR-BI [64],
NPC1 receptor [65] and tight junction molecules CLDN1 [66]
and OCLN [67] required for HCV cell entry. Nevertheless,
besides its reliance on the expression of receptor molecules,
initiation of a productive HCV infection depends on the
cholesterol content of the target cell membrane [22]. Indeed,
cholesterol constitutes an essential component of lipid-rich
membrane microdomains, organised parts of the plasma mem-
brane. These membrane domains compartmentalise/segregate
proteins and lipids and thus play a key role in virus entry, either
influencing clustering of receptors or acting on virus-cell fusion
[23,68].
Depletion of the membrane cholesterol with MbCD inhibited
HCV infection [22] showing for the first time that cholesterol-rich
raft environments are likely to serve as portals for HCV entry.
While MbCD disrupts lipid rafts by depleting cells of cholesterol
with high cytotoxicity [69], ABCA1 stimulation leads to the
activation of the physiological cholesterol efflux pathway that does
not affect total and free cellular cholesterol content, and has low
cytotoxicity. Whereas MbCD treatment resulted in important
changes of cell surface expression of CD81 and SR-BI [22] and
OCLN [70], such changes were not observed in our study in cells
over-expressing ABCA1. Indeed, using the Duo Link assay we
found that the cell surface distribution of SR-BI and CLDN1
relative to CD81, the HCV receptors supposed to co-localise
[22,49] was not modified in GW3965-stimulated cells (distance ,
40 nm).
Up-regulation of ABCA1 leads to a perturbation of cholesterol
packaging in cell membranes and induces changes in its
distribution in the lipid rafts or between raft and non-raft
microdomains [51,53,54,56]. Such modifications might impair
HCV-host cell fusion, as shown in our fusion assay, either by
influencing distribution of lipids and proteins or by changing
membrane fluidity [23].
Indeed, cholesterol facilitates HCV-mediated fusion dependent
upon the presence of functional E1 and E2 proteins [36]. The
fusion proteins act in common with lipid and cholesterol
assemblies at the virus-cell fusion step. Lipids, mainly glyceropho-
spholipids, sphingolipids and sterols, contribute through their
physical, mechanical and/or chemical properties, whereas choles-
terol plays a role through its preferential partitioning into rafts or
Figure 7. Analysis of cellular lipids in GW3965-treated cells.
Huh7.5 cells were treated with 1 mM GW3965 (GW3965) or drug solvent
(solvent). Cellular lipids were extracted and (A) cellular total cholesterol,
(B) cell-free cholesterol, (C) cholesterol esters and (D) triglyceride levels
were quantified and expressed relative to total protein levels.
doi:10.1371/journal.pone.0092140.g007
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its binding affinity for certain viral envelope proteins. Cholesterol-
rich microdomains are implicated in the entry of many virus
species such as Ebola and Marburg viruses, Vaccinia virus, murine
hepatitis virus, lymphocytic choriomeningitis virus and Herpes
Simplex Virus. Indeed, cholesterol dispersion or reorganisation of
lipid microdomains using drugs such as filipin and nystatin
reduced virus entry, although virion attachment was unaffected.
Since all these viruses enter host cell via cholesterol-rich
microdomains, these observations suggested drug action on a
fusion step [71].
Several studies underline the fact that ABCA1 expression does
not alter the overall cellular cholesterol content or its subcellular
distribution [53]. The current model proposes that ABCA1 exerts
an influence on plasma membrane structure, modifying the
organisation of cholesterol-rich microdomains by redistributing
cholesterol/sphingolipids to non-raft domains that facilitates
ApoA1 interaction and efflux [51,53,54,56]. In agreement with
this notion, in our study activation of the ABCA1 pathway had
only a minor effect on total and free cholesterol content in Huh7.5
cells. Instead, stimulation of ABCA1 modified the cholesterol
distribution in cell membranes. Indeed, lipid raft-dependent
localisation of GFP-FR in membranes was dramatically changed
in GW3965-treated cells. These changes most probably disturbed
virus-cell entry, confirming that the integrity of cholesterol-rich
membrane microdomains is essential for the initiation of a
productive HCV infection.
Supplying a surplus of exogenous cholesterol to GW3965-
treated cells overturned the inhibitory effect on HCV cell entry, in
accordance with the notion that adding exogenous cholesterol to
cells that over-express ABCA1 tightens lipid packaging in raft and
non-raft microdomains, while decreasing ABCA1-dependent
cholesterol efflux [56].
HCV (JFH-1 strain) infection of the Huh7.5 cell line is currently
used for studies of the HCV life cycle and the evaluation of HCV
inhibitors. Nevertheless, this in vitro cell culture system, based on
transformed and poorly differentiated hepatoma cells, has several
Figure 8. Analysis of HCV particles secreted from cells that over-express ABCA1. Physical properties of the nascent virus particles
produced in cells stimulated or not with GW3965 were analysed by centrifugation in iodixanol gradient. Huh7.5 cells were pre-incubated with solvent
(panel A) or 1 mM GW3965 (panel B) and the drug was maintained until 72 h post-infection when cell supernatants were collected, concentrated and
subjected to gradient centrifugation. HCV RNA in gradient fractions was quantified by qRT-PCR and core antigen, ApoB and ApoE by ELISA assays.
doi:10.1371/journal.pone.0092140.g008
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Figure 9. GW3965 treatment does not change the expression of HCV receptors, but affects HCV-cell fusion and modifies lipid raft
structure. (A) Analysis of the expression of CD81, SR-BI and LDL-R in Huh7.5 cells treated with 1 mM GW3965 by Flow Cytometry using anti-receptor
antibodies. GW3965-stimulated cells are shown by bold lines and non-treated cells by plain lines. Filled histograms represent cells stained with the
secondary antibody only. (B) Western Blot assessment of the expression of OCLN, CLDN1 and NPC1 receptor in GW3965-treated cells, compared to
solvent-treated cells. Pan Cadherin (pCadh) was used as a loading control. (C) GW3965 treatment inhibits HCV envelope-induced cell fusion. 293T
cells that co-express a luciferase marker and the HCV E1–E2 envelope glycoproteins or the Chikungunya virus envelope glycoproteins were co-
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limitations, especially concerning lipoprotein metabolism [72].
Thus, we confirmed our findings in primary culture of human
hepatocytes and in human liver slices, which maintain the 3D
structure and gene expression of the liver with normal lipid/
lipoprotein metabolic pathways. We provide evidence that
stimulation of ABCA1 expression with GW3965 inhibits HCV
infection in primary hepatocytes even more efficiently than in
Huh7.5 cells.
HIV infection depends on membrane cholesterol for virus
assembly, budding as well as cell entry, which also requires lipid
cultured with Huh7-Tat indicator cells. Co-cultured cells were incubated with 1 mM GW3965 or DMSO and exposed to pH 5. Luciferase activity was
measured 72 h later. Data are presented as the fusion rate in the presence of the drug (black bars) relative to fusion in the absence of drug (gray
bars), which was considered as 100%. The graph represents the average of 3 independent experiments (*P,0.03). (D–E). Cholesterol loading
counteracts the inhibitory effect of ABCA1 over-expression on HCV infection. Huh7.5 cells were stimulated with 1 mM GW3965 to over-express
ABCA1, and then incubated with 20 mM cholesterol/MbCD. In (D) the determination of total cellular cholesterol after replenishment of ABCA1
overexpressing cells with cholesterol/MbCD is shown. GW3965-treated cells (black bars) were compared to solvent-treated (grey bars). The infection
of Huh7.5 cells after cholesterol supply is shown in (E). Intracellular HCV RNA was determined by qRT-PCR at 24 h post-infection, and is expressed as
the percentage of HCV RNA in drug-treated (black bars) compared to solvent-treated (grey bars) cells, supplied (+Chol) or not (wo Chol) with
cholesterol. (F) GW3965 treatment modifies plasma membrane organisation and thus the distribution of lipid raft-associated protein. Huh7.5 cells
were transfected with DNA encoding the Glycosylphosphatidyl-inositol-anchor attachment signal of the folate receptor fused to GFP (GFP-FR). Cells
were subsequently exposed to 1 mM GW3965 or drug solvent (control). Two days post-transfection cells were fixed and GFP-FR fluorescence was
visualised using a Zeiss axioplan 2 microscope (x63 objective). Slices of 0.46 mm were acquired. The images shown are a Z projection of 5 slices of the
cell surface that face the cell medium. The right panel represents GW3965-stimulated cells and the left control cells. The scale bar corresponds to
10 mm.
doi:10.1371/journal.pone.0092140.g009
Figure 10. Over-expression of ABCA1 inhibits HCV infection of primary human hepatocytes and human liver slices. (A–B) Inhibition of
HCV infection of primary human hepatocytes. (A) Primary human hepatocytes were treated with 2–10 mM GW3965 (non-toxic concentrations for
cells) or with drug solvent, prior to HCV infection. Twenty-four hours post-infection, ABCA1 mRNA was determined by qRT-PCR and expressed in
arbitrary units, taking into account ABCA1 levels in liver cells pre-treated with the drug. (B) GW3965-treated and solvent-treated primary human
hepatocytes were inoculated with HCV. After 24 h, intracellular HCV RNA was quantified by qRT-qPCR. The efficiency of infection in drug pre-treated
cells was expressed as the percentage of infection compared to solvent-treated cells. (C–D) ABCA1 over-expression inhibits HCV infection of human
liver slices. Human liver slices were cultured for 24 h, treated with 5 or 10 mM GW3965 or with DMSO before infection with HCVcc. At 24 h post-
infection, total RNA was extracted and ABCA1 mRNA (C) and HCV RNA (D) were quantified by corresponding qRT-PCR assays and expressed as the
percentage of RNA compared to the values obtained for solvent-treated cells.
doi:10.1371/journal.pone.0092140.g010
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rafts [73]. Strikingly, via its protein Nef, HIV down-regulates
ABCA1 expression and impairs cholesterol efflux activity to infect
its target cell [74]. ABCA1 overexpression achieved using the
TO901317 LXR agonist impaired HIV infection; accordingly,
pharmacological stimulation of ABCA1 has been proposed as an
approach to inhibit HIV infection [75].
ABCA1-mediated cholesterol efflux leads to the formation of
HDL, a lipoprotein preventing arteriosclerosis and cardiovascular
disease progression. New drugs are under development that should
reduce the side effects found for LXR agonists such as an increase
in triglyceride levels [76,77] also observed in our study. Moreover,
cholesterol efflux function has been linked to anti-tumour activity,
and thus ABCA1 is considered as a tumour-suppressor molecule
[78].
Our study suggests that in addition to other known beneficial
roles, ABCA1 emerges as a potential target to better control HCV
infection.
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